Linked Life Data

15109616

Source:http://linkedlifedata.com/resource/pubmed/id/15109616

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2004-4-27
pubmed:abstractText
Diagnostic, prognostic and therapeutic applications of B-type natriuretic peptides (NPs) will probably become part of routine management of heart failure within five years. Cardiac release of NPs rises with increasing cardiac dysfunction. Their secretion and plasma levels respond to intracardiac distending pressures, with other modulating influences including age, sex, renal function and other aspects of neurohormonal status. Single and serial plasma NP measurements, particularly of B-type and N-terminal pro-B-type NP, show promise in diagnosis of heart failure, risk stratification in those with known heart disease, and in adjustment of anti-failure therapy. Recombinant B-type NP is an effective parenteral treatment in decompensated heart failure. These applications of B-type NPs require confirmation before they become established in routine management of heart failure.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1043-2760
pubmed:author
pubmed:issnType
Print
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
170-4
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:articleTitle
Clinical applications of B-type natriuretic peptides.
pubmed:affiliation
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, P.O. Box 4345, Christchurch, New Zealand. mark.richards@cdhb.govt.nz
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't